2.36 0.00 (0.00%)
After hours: 4:30PM EDT
|Bid||2.25 x 4000|
|Ask||3.00 x 1300|
|Day's Range||2.32 - 2.39|
|52 Week Range||2.25 - 4.50|
|PE Ratio (TTM)||0.56|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.25|
This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning about how to value company based on its currentRead More...
Ophthotech (OPHT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ophthotech Corporation (OPHT) announced today that scientists at the University of Pennsylvania (Penn) and University of Florida published proof-of-concept study results on an adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) licensed by Ophthotech. In June 2018, Ophthotech announced that it entered into an exclusive global license agreement with the University of Florida Research Foundation and Penn for rights to develop and commercialize this novel AAV gene therapy product candidate for the treatment of RHO-adRP.
NEW YORK, Aug. 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Energy ...
The New York-based company said it had a loss of 37 cents per share. The company's shares closed at $2.49. A year ago, they were trading at $2.40. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) ...
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / Ophthotech Corp. (NASDAQ: OPHT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 8:00 AM Eastern Time. To ...
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Ophthotech Corporation (OPHT) filed a consolidated amended class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between March 2, 2015 and December 12, 2016. Ophthotech, a biopharmaceutical company, develops novel therapeutics to treat ophthalmic diseases. The company's most advanced product candidate was Fovista, an anti-platelet derived growth factor agent designed to treat wet age-related macular generation ("AMD").
Ophthotech Corporation (OPHT) today announced that it will report its second quarter 2018 financial and operating results on Wednesday, August 1, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update. A live, listen-only audio webcast of the conference call can be accessed on the Investor Relations section of the Ophthotech website at: www.ophthotech.com.
On Monday, July 16, 2018, the NASDAQ Composite and the S&P 500 edged 0.26% and 0.10% lower, respectively at the closing bell, while the Dow Jones Industrial Average stayed bullish, finishing marginally higher by 0.18%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Onconova Therapeutics Inc. (NASDAQ: ONTX), Ophthotech Corp. (NASDAQ: OPHT), OPKO Health Inc. (NASDAQ: OPK), and OvaScience Inc. (NASDAQ: OVAS).
BASKING RIDGE, N.J., July 10, 2018-- electroCore, Inc., a commercial-stage bioelectronic medicine company, today announced the appointment of Carrie S. Cox as Chairman of its Board of Directors, and Michael ...
NEW YORK, NY / ACCESSWIRE / June 8, 2018 / While Proteostasis Therapeutics announced positive results from an ongoing 14-day dosing study of PTI-801, an analyst at RBC Capital Markets didn't seem impressed and downgraded the company this week as well as lowered his price target on shares. Ophthotech Corporation saw a different story yesterday, gaining over 10% after announcing that it has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania. The results had shown statistically significant improvement in sweat chloride, body mass index, and weight and blood glucose.
Ophthotech Corporation (OPHT) announced today that it has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania (Penn) to develop and commercialize a novel adeno-associated virus (AAV) gene therapy product for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP), an orphan monogenic disease that is characterized by progressive and severe loss of vision leading to blindness. Preclinical anatomical and functional proof-of-concept studies have demonstrated promising results in a canine disease model. In addition to the exclusive license agreement, Ophthotech and Penn have also entered into a master sponsored research agreement, facilitated by the Penn Center for Innovation (PCI), pursuant to which Ophthotech and Penn plan to conduct preclinical and natural history studies.
On a per-share basis, the New York-based company said it had a loss of 36 cents. The company's shares closed at $2.62. A year ago, they were trading at $2.62. _____ This story was generated by Automated ...
Ophthotech Corporation today announced financial and operating results for the first quarter ended March 31, 2018 and provided a business update.
LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free research report on Ophthotech Corp. (NASDAQ: OPHT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OPHT as the Company's latest news hit the wire. On May 01, 2018, the New York-based biopharmaceutical Company announced that it has completed patient enrollment in its Phase-2a clinical trial of Zimura® (avacincaptad pegol) in patients with wet age-related macular degeneration (AMD).
Ophthotech Corporation (OPHT) today announced the completion of patient enrollment in its Phase 2a clinical trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). Zimura is administered in combination with Lucentis® (ranibizumab), an anti-vascular endothelial growth factor (anti-VEGF) agent, in treatment naïve patients with wet AMD. “We are pleased with the enthusiasm shown by the principal investigators in the recruitment for this clinical trial leading to on time enrollment of patients,” stated Kourous Rezaei, M.D., Chief Medical Officer of Ophthotech.
Ophthotech Corporation (OPHT) today announced that it will report its first quarter 2018 financial and operating results on Wednesday, May 9, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update. Ophthotech is a science-driven biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases.
Regeneron (REGN) announces encouraging top-line results from the phase III study evaluating Eylea injection in moderately severe to severe non-proliferative diabetic retinopathy.